Compositions and Methods of Use of EPB1, and ErbB3 Binding Protein

Inhibition of the proliferation of hormone refractory prostate cancer cells is achieved by administering EPB1, an ErbB3 binding protein, in combination with another anti-proliferation therapy such as administration of antiandrogens, other anticancer agents, radiation therapy, or surgery. Administration of EPB1 reverses the phenotype of hormone-resistant prostate cancer cells to hormone-sensitive prostate cancer cells.

Attached files:


Patents:
US 7,838,495   [MORE INFO]

Inventor(s): ZHANG YUEXING [US]; HAMBURGER ANNE [US]

Type of Offer: Licensing



« More Biotech Patents

---